Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
322
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,777.90 | 50.80 | -0.58% |
CAC 40 | 7,878.46 | 111.75 | 1.44% |
DAX 40 | 24,549.56 | 342.65 | 1.42% |
Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
FTSE 100 | 8,867.02 | 12.84 | 0.15% |
HKSE | 23,892.32 | 255.75 | -1.06% |
NASDAQ | 20,611.34 | 192.87 | 0.94% |
Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
NZX 50 Index | 12,782.42 | 13.81 | 0.11% |
S&P 500 | 6,263.26 | 37.74 | 0.61% |
S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
SSE Composite Index | 3,493.05 | 4.43 | -0.13% |